IP Library › Granted Patent US 11,779,598
Granted Patent B2
US 11,779,598 · App. 17/513,990 · Granted Oct 10, 2023

Synthesis and antimicrobial uses of dinuclear silver(I) pyrazolates

Inventors: Raphael G. Raptis (Miami, FL); Indranil Chakraborty (Miami, FL); Shambhu Kandel (Miami, FL)
Assignee: THE FLORIDA INTERNATIONAL UNIVERISTY BOARD OF TRUSTEES
A61K33/38A61P31/04C07F1/005C07F9/65848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,598
App. No.
17/513,990
Granted
Oct 10, 2023
Kind
B2
Abstract

Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided.

Claims (20)

1. A dinuclear silver (I) pyrazolido complex having the following structure (C)

wherein R 1 and R 2 are each independently selected from the group consisting of 1,3,5-triaza-7-phosphaadamantane (PTA), phosphaadamantane (PA), P(R 6 ) 3 , (4-sulfophenyl)diphenylphosphine (SDPP), phenanthrene diphenylphosphine (PDPP), 8-((4-phosphino)phenyl)-4,4-dimethyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (PMBODIPY), 8-((4-phosphino)phenyl)-4,4-diethyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene(PEBODIPY), and 8-((4-phosphino)phenyl)-4,4-diphenyl-1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (PPBODIPY);

m is 1;

n is 1;

R 3 , and R 5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, hydroxyalkyl, halogen substituted alkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantine, imine-linked triphenylphosphine, and amine-linked triphenylphosphine; and each R 6 is independently selected from the group consisting of alkyl and aryl, and

R 4 is selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, hydroxyalkyl, halogen substituted alkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantine, imine-linked triazaadamantine, amine-linked triazaadamantine, imine-linked triphenylphosphine, and amine-linked triphenylphosphine;

or a pharmaceutically acceptable salt thereof.

2. The dinuclear silver(I) pyrazolido complex, according to claim 1 ,

wherein R 3 , and R 5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, hydroxyalkyl, halogen substituted alkyl, halogen substituted aryl, and halogen substituted sulfuryl.

3. The dinuclear silver(I) pyrazolido complex, according to claim 1 ,

wherein R 1 and R 2 are PA; and R 3 , and R 5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, halogen substituted alkyl, hydroxyalkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantine, imine-linked triphenylphosphine, and amine-linked triphenylphosphine.

4. The dinuclear silver(I) pyrazolido complex, according to claim 1 , wherein R 3 is hydrogen; and R 5 is selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, alkyl, alkenyl, aryl, formyl, acetyl, hydroxyalkyl, halogen substituted alkyl, halogen substituted aryl, halogen substituted sulfuryl, imine-linked PTA, amine-linked PTA, imine-linked adamantane, amine-linked adamantine, imine-linked triphenylphosphine, and amine-linked triphenylphosphine.

5. The dinuclear silver (I) pyrazolido complex, according to claim 1 , wherein R 1 and R 2 are PA;

R 3 and R 5 are each independently hydrogen, nitro, chloride or methyl;

R 4 is selected from the group consisting of nitro, methyl, hydroxyethyl, SO 2 Cl, imine-linked PTA, amine-linked PTA, amine-linked triazaadamantine and phenyl.

6. The dinuclear silver (I) pyrazolido complex, according to claim 1 , wherein R 3 is selected from the group consisting of hydrogen, nitro, and chloride; R 5 is selected from the group consisting of hydrogen, nitro, chloride and methyl; and

R 4 is imine-linked triazaadamantine or amine-linked triazaadamantine.

7. A composition comprising a dinuclear silver (I) pyrazolido complex according to claim 1 .

8. The composition according to claim 7 , further comprising one or more ingredients selected from anti-bacterial agents, anti-viral agents, fungicidal agents, anesthetic agents, buffers, and pharmacological excipients.

9. The dinuclear silver (I) pyrazolido complex according to claim 1 , wherein the dinuclear silver (I) pyrazolido complex is:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2021
From: RAPTIS, RAPHAEL G.; CHAKRABORTY, INDRANIL; KANDEL, SHAMBHU
To: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Reel/Frame 058147/0747 →
Continuity (4)
Continuation 16932075 · Jul 17, 2020
Continuation 16456834 · Jun 28, 2019
Provisional Application 62722664 · Aug 24, 2018
Related Publication 20220047628A1 · Feb 17, 2022